We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Civica Rx, a two-year-old nonprofit organization launched to address generic drug shortages in the U.S., announced that drugmaker Catalent and health insurance giant Anthem are joining the organization’s new CivicaScript operating unit that focuses on making generic drugs. Read More
GSK is expanding its reach in cancer immunotherapies in a $2.1 billion deal with iTeos Therapeutics to co-develop EOS-448, a monoclonal antibody aimed at getting the body’s immune system to recognize and attack cancer cells. Read More
The U.S. government will pay Merck an estimated $1.2 billion for 1.7 million courses of its experimental COVID-19 antiviral, molnupiravir, if the drug is authorized by the FDA. Read More
Saying that the COVID-19 crisis “laid bare new and longstanding drug supply-chain vulnerabilities,” the Biden administration yesterday proposed sweeping changes for the U.S. drug industry to restore its control over drug ingredients and quality. Read More
Johnson & Johnson (J&J) has decided to call it quits on its global collaboration and licensing agreement with Argenx, an arrangement for a blood cancer drug hashed out in late 2018 that was worth up to $1.6 billion. Read More
Abernethy will join Robert Califf, the former FDA commissioner from 2016-2017 now serving as the biotech’s head of clinical policy and strategy. Read More
Constellation’s pelabresib has potential to be “a first- and best-in-class BET inhibitor” and is currently in a phase 3 clinical trial for myelofibrosis. Read More